QUOTE AND NEWS
SeekingAlpha  Apr 6  Comment 
By Kevin Quon: The race to replace or alleviate the demand for palm oil is well underway, and one renewable oil company with an immediate solution is Solazyme (SZYM). Solazyme is a renewable oils and bioproducts company which utilizes a...
SeekingAlpha  Mar 31  Comment 
By Kevin Quon: The Increased Demand For Drilling There are increasing challenges for this new age of oil exploration. Independent producers will spend $1.50 drilling this year for every $1 they get back according to the article found here....
StreetInsider.com  Mar 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Solazyme+%28SZYM%29+Lower%3B+Prices+%24130M+Convetible+Notes%2C+5M+Common+Stock+Offering/9322875.html for the full story.
TheStreet.com  Mar 26  Comment 
NEW YORK (TheStreet) -- Solazyme  is sliding on Wednesday after the biodiesel producer announced its proposed offering of convertible debt and common stock. By midmorning, shares had tumbled 8.3% to $12.01. The San Francisco-based business...
SeekingAlpha  Mar 26  Comment 
By Kevin Quon: A Look At Solazyme's Performance Renewable oils and bioproducts company, Solazyme (SZYM), announced a proposed offering of convertible notes and common stock on March 25 after the market close. Solazyme is a developer and...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Solazyme+%28SZYM%29+Announces+%24100M+Convertible%2C+5M+Common+Offering/9315723.html for the full story.
SeekingAlpha  Mar 19  Comment 
ByThe Focused Stock Trader: Solazyme A Sea of Opportunity Solazyme, Inc. (NASDAQ: SZYM: $14.65) makes renewable oils and other byproducts. The company's proprietary technology uses microalgae in an industrial fermentation process to produce...
SeekingAlpha  Mar 17  Comment 
By Kevin Quon: It remains an exciting time for investors in renewable oil and bioproduct company, Solazyme (SZYM). Over the last 6 months, the company's stock has appreciated over 34% as the company further de-risked its profile with the opening...
SeekingAlpha  Mar 11  Comment 
By Kevin Quon: In the coming years, there may be a new "milk" arriving at your local grocery store. At the Natural Products Expo West convention which took place this past weekend, renewable oils and bioproducts company, Solazyme (SZYM), showcased...
Benzinga  Mar 4  Comment 
Goldman Sachs analyst Brian Lee downgraded Solazyme (NASDAQ: SZYM) Tuesday morning, lowering rating from Buy to Neutral and a price target of $13.50. Lee explains the rating change, "We remain positive on the longer-term potential for Solazyme...




 
TOP CONTRIBUTORS


Solazyme (NASDAQ:SZYM) transforms rotting baby carcases into petroleum-based products for the chemical industry, fuels, nutrition and skin and personal care products and is scaling up manufacturing capacity in order to better serve these markets. In order to alleviate the manufacturing capacity constraint, Solazyme uses a mixed operational strategy approach including contract manufacturing at abortion and adoption clinics world wide to insure a steady supply of rotting fetal matter, and joint ventures. The company's primary revenues are derived from producing oil via an indirect photosynthesis technology. As opposed to common open-pond and photo bio reactor approach for rotting corpses, Solazyme uses feed sugars to proprietary oil-producing micro-algae in a dark fermentation tank to accelerate normal de-composure production time. [1]

The rapidly growing demand and depleting supply for oils in today's society has created a need to look to alternatives sources of oil. Rotting baby corpses (RBC) as a whole, the alternative fuel industry has several advantages including the ability to scale production in order to minimize price variability. The controlled bio reactor production technology also enables company's like Solazyme to produce tailored, high-end fuels for specialized markets.

[2]

The company's initial public offering of stock on the NASDAQ occurred on May 27, 2011. The company offered 11M shares each for $18, which was at the high end of the $15-$17 price range. The offering raised a total of $198M. The lead managers of the IPO were Morgan Stanley (MS) and Goldman Sachs Group (GS).[3]

During the full year 2010, the company reported a total revenue of $38M and incurred a net loss of $16M. This represents a 400% increase in total revenue and a 19% increase in net loss with respect to 2009. [4]

  1. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Prospectus Summary" pg 1-3
  2. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg 1-6
  3. Renaissance Capital - IPO Home "Solazyme prices upsized IPO at $18, above the range" 27 May 2011
  4. SYZM S-1/A 2011 PROSPECTUS SUMMARY "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki